Related Experiment Video
Updated: Jun 18, 2026
The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Molecular profiling of small renal masses: Current status and future directions
Balaji Kalyanaraman1, Krishnanath Gaitonde, James F Donovan
1Division of Urology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Abstract:
Small renal masses (SRMs) are renal tumors less than 4 cm in diameter. These account for the largest proportion of newly diagnosed renal cell cancers (RCC). Management of SRMs can be a dilemma if the patient is unfit to undergo partial nephrectomy. Molecular profiling enables better characterization of RCC and prediction of outcomes in terms of recurrence and progression. This article reviews the existing literature on molecular profiling of localized RCC, discusses limitations of molecular profiling, and presents the likely role that molecular profiling will play in guiding the treatment of SRMs.
Insights
Molecular profiling aids in understanding small renal masses (SRMs), which are common kidney cancers. This approach helps predict recurrence and progression, guiding treatment for patients unfit for surgery.
Area of Science:
- Urology
- Oncology
- Genomics
Background:
- Small renal masses (SRMs) represent the majority of newly diagnosed kidney cancers.
- Management challenges arise for SRMs in patients unsuitable for partial nephrectomy.
Purpose of the Study:
- To review literature on molecular profiling of localized renal cell cancer (RCC).
- To discuss limitations of current molecular profiling techniques.
- To explore the future role of molecular profiling in SRM treatment decisions.
Main Methods:
- Comprehensive literature review of studies on molecular profiling in localized RCC.
- Analysis of existing data on recurrence and progression prediction.
- Discussion of technological and clinical limitations.
Main Results:
- Molecular profiling offers enhanced characterization of RCC.
- It shows potential in predicting tumor recurrence and progression.
- Current limitations include standardization and accessibility.
Conclusions:
- Molecular profiling is crucial for personalized treatment of SRMs.
- It may guide management decisions, especially for patients with surgical contraindications.
- Further research is needed to overcome limitations and integrate profiling into clinical practice.
